Robert Harrington  
Arthur L. Bloomfield Professor of Medicine, Emeritus

Bio

ACADEMIC APPOINTMENTS

- Honorary Faculty Emeritus, Medicine
- Member, Cardiovascular Institute

Publications

PUBLICATIONS

- **Sex Differences in Revascularization, Treatment Goals, and Outcomes of Patients With Chronic Coronary Disease: Insights From the ISCHEMIA Trial.** *Journal of the American Heart Association*
  2024: e029850

- **Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease.** *Journal of the American Heart Association*
  2024: e026921

- **Two of a kind: mass and molar immunoassay-based lipoprotein (a) concentrations are similarly prognostic for MACE risk and predictive of alirocumab benefit in ODYSSEY OUTCOMES**
  OXFORD UNIV PRESS.2023

- **GDF-15 is associated with worse ischemic and bleeding outcomes in the acute phase and during follow-up in patients with acute coronary syndrome: insights from the TRACER trial**
  OXFORD UNIV PRESS.2023

- **Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.** *Journal of the American Heart Association*
  2023: e030385

- **Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.** *JAMA cardiology*
  2023
• Personalized digital behaviour interventions increase short-term physical activity: a randomized control crossover trial substudy of the MyHeart Counts Cardiovascular Health Study. *European heart journal. Digital health*
  2023; 4 (5): 411-419

• Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. *Diabetes care*
  2023

• Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial. *Journal of the American Heart Association*
  2023: e029216

• Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of Three Tests. *Circulation*
  2023

• Impact of Complete Revascularization in the ISCHEMIA Trial. *Journal of the American College of Cardiology*
  2023

• Internet Versus Noninternet Participation in a Decentralized Clinical Trial: Lessons From the ADAPTABLE Study. *Journal of the American Heart Association*
  2023: e027899

• Comparison of the effectiveness and safety of two aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: a subgroup analysis of ADAPTABLE. *American heart journal*
  2023

• Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome. *The Canadian journal of cardiology*
  2023

• Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. *European heart journal*
  2023

• Sociodemographic determinants of oral antiocoagulant prescription in patients with atrial fibrillations: findings from the PINNACLE registry using machine learning. *Heart rhythm O2*
  2023; 4 (3): 158-168

• Temporal Trends in Gender of Principal Investigators and Patients in Cardiovascular Clinical Trials. *Journal of the American College of Cardiology*
  Yong, C., Suvarna, A., Harrington, R., Gummipundi, S., Krumholz, H. M., Mehran, R., Heidenreich, P.
  2023; 81 (4): 428-430
• External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial. *Journal of thrombosis and thrombolysis*
  2022

• Survival After Invasive or Conservative Management of Stable Coronary Disease. *Circulation*
  2022

• Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes. *Journal of the American College of Cardiology*
  2022; 80 (18): 1735-1747

• External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry. *International journal of cardiology*
  2022

• Blood pressure and clinical outcomes in patients with diabetes and stable coronary artery disease in THEMIS
  OXFORD UNIV PRESS. 2022: 1226

• Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: further insights from the ODYSSEY OUTCOMES trial
  OXFORD UNIV PRESS. 2022: 1233

• Lipoprotein(a) and the effect of alirocumab on coronary and non -coronary revascularization following acute coronary syndrome
  OXFORD UNIV PRESS. 2022: 1386

• Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. *Journal of clinical lipidology*
  2022

• Response by Cavender et al to Letter Regarding Article, ”Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX” *CIRCULATION-CARDIOVASCULAR INTERVENTIONS*
  Cavender, M. A., Harrington, R. A., Bhatt, D. L.
  2022; 15 (7): 636-637

• Trials and Tribulations of Randomized Clinical Trials. *Circulation*
  Harrington, R. A.
  2022

• Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. *Circulation*
  2022: 101161CIRCUATIONAHA121057807

• A Retrospective Analysis of Medical Student Performance Evaluations, 2014-2020: Recommend with Reservations. *Journal of general internal medicine*
  2022
iterative approaches to the use of electronic health records data for large pragmatic studies. Contemporary clinical trials

2022: 106789

Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. European heart journal. Cardiovascular pharmacotherapy

2022

Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial. Circulation. Cardiovascular interventions

2022: CIRCINTERVENTIONS121010925

Balance of Benefit and Risk of Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease According to Bleeding Risk Assessment With the CRUSADE Score: Data From THEMIS and THEMIS PCI: Abbreviated title: Bleeding risk stratification of ticagrelor. American heart journal

2022

Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial. The american journal of medicine

2022

Changing the Trajectory of Heart Failure and Kidney Disease. Clinical journal of the American Society of Nephrology : CJASN

Rangaswami, J., Bhalla, V., Chertow, G., Harrington, R., Staruschenko, A., Tuttle, K., Braunwald, E.
2022

Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATElet inhibition and patients Outcomes (PLATO) trial. European heart journal. Acute cardiovascular care

2022

Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. Circulation. Cardiovascular interventions

2022: CIRCINTERVENTIONS121011069

Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA

Bhatt, D. L., Lopes, R. D., Harrington, R. A.
2022: 327 (7): 662-675

Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial. Thrombosis research

1800; 211: 63-69

Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. Circulation. Cardiovascular interventions

1800: CIRCINTERVENTIONS120010390

The Pivotal Role of Women in Cardiology Sections in Medical Organizations: From Leadership Training to Personal Enrichment. CJC open

1800; 3 (12 Suppl): S95-S101
- **Women’s health in Serbia - past, present, and future** *SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO*
  2021; 149 (11-12): 745-754

- **Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials.** *JAMA network open*
  2021; 4 (7): e2117963

- **Increases in SARS-CoV-2 Test Positivity Rates Among Hispanic People in a Northern California Health System.** *Public health reports (Washington, D.C. : 1974)*
  Rodriguez, F., Coquet, J., Harrington, R., Hernandez-Boussard, T.
  2021; 333549211026778

- **Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease** *NEW ENGLAND JOURNAL OF MEDICINE*
  2021; 384 (21): 1981-1990

- **Global Prevalence and Impact of Hostility, Discrimination, and Harassment in the Cardiology Workplace.** *Journal of the American College of Cardiology*
  2021; 77 (19): 2398-2409

- **Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.** *The New england journal of medicine*
  2021

- **Antithrombotic Therapy after Acute Coronary Syndromes** *REPLY NEW ENGLAND JOURNAL OF MEDICINE*
  Rodriguez, F., Harrington, R. A.
  2021; 384 (19): 1873-1874

- **Nonprofit Advocacy at the American Heart Association: Creating a Visionary Way Forward at Our 40th Anniversary: An American Heart Association Policy Statement** *CIRCULATION*
  2021; 143 (19): E947-E958

- **GENDER DISPARITIES IN CARDIOLOGY-RELATED COVID-19 PUBLICATIONS**
  Vasti, E., Ouyang, D., Ngo, S., Harrington, R., Rodriguez, F.
  ELSEVIER SCIENCE INC.2021: 3105

- **A Return to Normal Is Not Good Enough.** *Circulation*
  Elkind, M. S., Harrington, R. A., Lloyd-Jones, D. M.
  2021; 143 (18): e893–e897

- **Establishing a Data Science Unit in an Academic Medical Center: An Illustrative Model.** *Academic medicine : journal of the Association of American Medical Colleges*
  2021

- **Temporal Trends in the Proportion of Women Physician Speakers at Major Cardiovascular Conferences.** *Circulation*
  Yong, C. M., Balasubramanian, S., Douglas, P. S., Agarwal, P., Birgersdotter-Green, U., Gummidipundi, S., Batchelor, W., Duvernoy, C. S., Harrington, R. A., Mehran, R.
  2021; 143 (7): 755–57

- **Taking a Stand Against Air Pollution - The Impact on Cardiovascular Disease: A Joint Opinion from the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology.** *Global heart*
  Brauer, M., Casadei, B., Harrington, R. A., Kovacs, R., Sliwa, K., WHF Air Pollution Expert Group
Taking a Stand Against Air Pollution-The Impact on Cardiovascular Disease: A Joint Opinion from the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology. *Journal of the American College of Cardiology*

Brauer, M., Casadei, B., Harrington, R. A., Kovacs, R., Sliwa, K., WHF Air Pollution Expert Group

2021

COVID-19 at 1 Year: American Heart Association Presidents Reflect on the Pandemic. *Circulation*

Elkind, M. S., Harrington, R. A., Lloyd-Jones, D. M.

2021; 143 (9): e746–e748

Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. *Circulation. Cardiovascular interventions*


2021: CIRCINTERVENTIONS120011035

The Need to Expand the Framework of Environmental Determinants of Cardiovascular Health From Climate Change to Planetary Health: Trial by Wildfire. *Circulation*

Chang, A. Y., Barry, M., Harrington, R. A.

2021; 143 (21): 2029-2031

Gender Disparities in Cardiology-Related COVID-19 Publications. *Cardiology and therapy*


2021

Antithrombotic Therapy after Acute Coronary Syndromes. *The New England journal of medicine*

Rodriguez, F. n., Harrington, R. A.

2021; 384 (19): 1873–74


Rodriguez, F. n., Harrington, R. A.

2021; 384 (5): 452–60

Risk Stratification Science Goes to a New Level. *JAMA cardiology*

Harrington, R. A., Ohman, E. M.

2020

Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease with a history of PCI: an economic evaluation of THEMIS-PCI using a Swedish healthcare perspective


OXFORD UNIV PRESS.2020: 3538

Effect of alirocumab on incidence of atrial fibrillation after acute coronary syndromes: insights from ODYSSEY OUTCOMES


OXFORD UNIV PRESS.2020: 500

Low-density lipoprotein cholesterol < 50 mg/dL is an appropriate target after acute coronary syndrome: propensity score-match analysis of the ODYSSEY OUTCOMES trial


OXFORD UNIV PRESS.2020: 1736
• Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. European heart journal
2020

• The Impact of Novel Coronavirus COVID-19 on Non-Communicable Disease Patients and Health Systems: A Review. Journal of internal medicine
Chang, A. Y., Cullen, M. R., Harrington, R. A., Barry, M.
2020

• In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < #7% are associated with lower major cardiovascular events. American heart journal
2020; 225: 97–107

• Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Heart rhythm
2020

• Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Journal of the American College of Cardiology
2020

• Protecting Medical Trainees on the COVID-19 Frontlines Saves Us All. Circulation
Harrington, R. A., Elkind, M. S., Benjamin, I. J.
2020

• Video-based AI for beat-to-beat assessment of cardiac function. Nature
2020; 580 (7802): 252-256

• Video-based AI for beat-to-beat assessment of cardiac function NATURE
2020

• Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. JAMA cardiology
2020

• Role of the American Heart Association in the Global COVID-19 Pandemic. Circulation
Elkind, M. S., Harrington, R. A., Benjamin, I. J.
2020

• Advancing Healthcare Reform: The American Heart Association’s 2020 Statement of Principles for Adequate, Accessible, and Affordable Health Care: A Presidential Advisory From the American Heart Association CIRCULATION
2020; 141 (10): E601–E614

• Call to Action: Rural Health: A Presidential Advisory From the American Heart Association and American Stroke Association CIRCULATION
2020; 141 (10): E615–E644

• Machine learning to predict venous thrombosis in acutely ill medical patients. Research and practice in thrombosis and haemostasis
• Deep learning interpretation of echocardiograms. *NPJ digital medicine*
  2020; 3 (1): 10

• Machine learning to predict venous thrombosis in acutely ill medical patients *RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS*
  2020

• Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. *Journal of the American College of Cardiology*
  2020; 75 (2): 133–44

• Deep learning interpretation of echocardiograms. *NPJ digital medicine*
  2020; 3: 10

• Machine learning and atherosclerotic cardiovascular disease risk prediction in a multi-ethnic population. *NPJ digital medicine*
  2020; 3 (1): 125

• Association of Burnout, Professional Fulfillment, and Self-care Practices of Physician Leaders With Their Independently Rated Leadership Effectiveness. *JAMA network open*
  2020; 3 (6): e207961

• Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. *Circulation*
  2020

• Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. *The New England journal of medicine*
  2020

• Management of Coronary Disease in Patients with Advanced Kidney Disease. *The New England journal of medicine*
  2020

• Protecting Our Front Line. *Circulation. Cardiovascular interventions*
  Harrington, R. A., Warner, J. J.
  2020; 13 (5): e009406

• A Path Forward. *Journal of the American Heart Association*
  Elkind, M. S., Harrington, R. A., Lloyd-Jones, D. M.
  2020; e018288

• Initial Invasive or Conservative Strategy for Stable Coronary Disease. *The New England journal of medicine*
  2020

• Machine learning and atherosclerotic cardiovascular disease risk prediction in a multi-ethnic population. *NPJ digital medicine*
  2020; 3: 125

• Safe Reintroduction of Cardiovascular Services during the COVID-19 Pandemic: Guidance from North American Society Leadership. *Journal of the American College of Cardiology*
2020

Safe Reintroduction of Cardiovascular Services during the COVID-19 Pandemic: Guidance from North American Societies. *The Canadian journal of cardiology*
2020

Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. *Journal of the American College of Cardiology*
2020; 75 (18): 2297–2308

Generating evidence for therapeutic effects: the need for well-conducted randomized trials. *The Journal of clinical investigation*
Califf, R. M., Curtis, L. H., Harrington, R. A., Hernandez, A. F., Peterson, E. D.
2020

Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week. *Journal of the American College of Cardiology*
2020; 76 (5): 580–89

Characteristics and Strength of Evidence of COVID-19 Studies Registered on ClinicalTrials.gov. *JAMA internal medicine*
2020

Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. *Journal of the American College of Cardiology*
2020; 76 (2): 162–71

2019; 50 (12): 3331–32

Association Between Current and Future Annual Hospital Percutaneous Coronary Intervention Mortality Rates *JAMA CARDIOLOGY*

The effect of digital physical activity interventions on daily step count: a randomised controlled crossover substudy of the MyHeart Counts Cardiovascular Health Study *LANCET DIGITAL HEALTH*
2019; 1 (7): E344–E352

The effect of digital physical activity interventions on daily step count: a randomised controlled crossover substudy of the MyHeart Counts Cardiovascular Health Study. *The Lancet. Digital health*
2019; 1 (7): e344-e352

2019 ACC Health Policy Statement on Cardiologist Compensation and Opportunity Equity *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
2019; 74 (15): 1947–65
• Efficacy of alirocumab treatment after acute coronary syndrome according to new ACC/AHA guidelines for lipid-lowering therapy
  OXFORD UNIV PRESS.2019: 2474

• Beyond duty hours: leveraging large-scale paging data to monitor resident workload  NPJ DIGITAL MEDICINE
  Kaushal, A., Katznelson, L., Harrington, R. A.
  2019; 2: 87

• Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial  JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
  2019; 74 (9): 1167–76

• Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.  Circulation
  2019

• Consequences of Slow Progress Toward Pragmatism in Randomized Clinical Trials: It Is Time to Get Practical.  JAMA cardiology
  Rodriguez, F., Califf, R. M., Harrington, R. A.
  2019

• Ticagrelor in Patients with Stable Coronary Disease and Diabetes.  The New England journal of medicine
  2019

  2019

• Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.  The lancet. Diabetes & endocrinology
  2019

• Trends in overall, cardiovascular and cancer-related mortality among individuals with diabetes reported on death certificates in the United States between 2007 and 2017  DIABETOLOGIA
  2019; 62 (7): 1185–94

• Characteristics of Digital Health Studies Registered in ClinicalTrials.gov  JAMA INTERNAL MEDICINE
  2019; 179 (6): 838–40

• Stanford Cardiovascular Institute At the Forefront of Cardiovascular Research  CIRCULATION RESEARCH
  Wu, J. C., Woo, Y., Mayerle, M., Harrington, R. A., Quertermous, T.
  2019; 124 (10): 1420–24

• Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?  EUROPEAN HEART JOURNAL
  2019; 40 (18): 1466–+

• Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women  CIRCULATION-CARDIOVASCULAR INTERVENTIONS
2019; 12 (5)

- Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study CLINICAL CARDIOLOGY
2019; 42 (5): 498–505

- Trends in overall, cardiovascular and cancer-related mortality among individuals with diabetes reported on death certificates in the United States between 2007 and 2017. Diabetologia
2019

- Physical activity, sleep and cardiovascular health data for 50,000 individuals from the MyHeart Counts Study SCIENTIFIC DATA
2019; 6

- Physical activity, sleep and cardiovascular health data for 50,000 individuals from the MyHeart Counts Study. Scientific data
2019; 6 (1): 24

- Sex Differences in the Pursuit of Interventional Cardiology as a Subspecialty Among Cardiovascular Fellows-in-Training (vol 12, pg 219, 2019) JACC-CARDIOVASCULAR INTERVENTIONS
2019; 12 (7): 695

- Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy INTENSIVE CARE MEDICINE
2019; 45 (4): 477–87

- It is time to learn from patients like mine. NPJ digital medicine
Gombar, S., Callahan, A., Califf, R., Harrington, R., Shah, N. H.
2019; 2: 16

- It is time to learn from patients like mine NPJ DIGITAL MEDICINE
Gombar, S., Callahan, A., Califf, R., Harrington, R., Shah, N. H.
2019; 2

- Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial. Journal of the American College of Cardiology
2019

2019; 12 (3): e007445

- What Is Needed Now to Improve Cardiovascular Clinical Registries in the Future JAMA CARDIOLOGY
Hernandez, A. F., Harrington, R. A.
2019; 4 (3): 201-202

- Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial JAMA CARDIOLOGY
• Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. JAMA cardiology
2019

• Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. Circulation
2019; 139 (9): 1234–36

• Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients An APEX Substudy. CIRCULATION
2019; 139 (9): 1234-1236

• Characteristics of Digital Health Studies Registered in ClinicalTrials.gov. JAMA internal medicine
2019

• Rationale, Design, and Baseline Characteristics of THEMIS: Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study. Clinical cardiology
2019

• What Is Needed Now to Improve Cardiovascular Clinical Registries in the Future. JAMA cardiology
Hernandez, A. F., Harrington, R. A.
2019

• Association Between Female Corresponding Authors and Female Co-Authors in Top Contemporary Cardiovascular Medicine Journals. Circulation
Ouyang, D., Harrington, R. A., Rodriguez, F.
2019; 139 (8): 1127–29

• Association Between Female Corresponding Authors and Female Co-Authors in Top Contemporary Cardiovascular Medicine Journals. CIRCULATION
Ouyang, D., Harrington, R. A., Rodriguez, F.
2019; 139 (8): 1127-1129

• Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive care medicine
2019

• One Size Does Not Fit All: Improving Recruitment and Retention of Women in Cardiovascular Device-Related Clinical Trials. JACC. Cardiovascular interventions
Rodriguez, F., Harrington, R. A.
2019; 12 (3): 309–11

• Sex Differences in the Pursuit of Interventional Cardiology as a Subspecialty Among Cardiovascular Fellows-in-Training JACC-CARDIOVASCULAR INTERVENTIONS
2019; 12 (3): 219-228

• One Size Does Not Fit All Improving Recruitment and Retention of Women in Cardiovascular Device-Related Clinical Trials JACC-CARDIOVASCULAR INTERVENTIONS
Rodriguez, F., Harrington, R. A.
2019; 12 (3): 309-311

• Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
2019; 73 (4): 387–96

Sex Differences in the Pursuit of Interventional Cardiology as a Subspecialty Among Cardiovascular Fellows-in-Training. *JACC. Cardiovascular interventions*
2019

Stanford Cardiovascular Institute. *Circulation research*
2019; 124 (10): 1420–24

Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. *Journal of the American College of Cardiology*
2019; 74 (9): 1177–86

A novel noninvasive method for remote heart failure monitoring: the EuleriAn video Magnification apPLications In heart Failure study (AMPLIFY). *NPJ digital medicine*
Abnousi, F., Kang, G., Giacomini, J., Yeung, A., Zarafshar, S., Vesom, N., Ashley, E., Harrington, R., Yong, C.
2019; 2: 80

Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. *Circulation. Cardiovascular interventions*
2019; 12 (8): e007604

Thrombophilia testing in the inpatient setting: impact of an educational intervention. *BMC medical informatics and decision making*
2019; 19 (1): 167

Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. *Circulation*
2019; 140 (13): 1115–24

10 Recommendations to Enhance Recruitment, Retention, and Career Advancement of Women Cardiologists. *Journal of the American College of Cardiology*
2019; 74 (14): 1839–42

Translating Science Into Policy. *Circulation*
Harrington, R. A., Churchwell, K. n., Whitisel, L. P.
2019; 140 (10): e545–e546

Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial *AMERICAN JOURNAL OF HEMATOLOGY*
2019; 94 (1): 21–28

Prehospital Phase of Acute Stroke Care: Guideline and Policy Considerations as Science and Evidence Rapidly Evolve. *Stroke*
Harrington, R. A.
2019: STROKEAHA119025584

Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women. *Circulation. Cardiovascular interventions*
2019; 12 (5): e007086
• Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. *Circulation*
  2019

• Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. *European heart journal*
  2019

• Burnout and Career Satisfaction Among U.S. Cardiologists. *Journal of the American College of Cardiology*
  2019; 73 (25): 3345–48

• The efficacy and safety of cangrelor in single vessel vs multi vessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. *Clinical cardiology*
  2019

• Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. *American heart journal*
  2019; 215: 106–13

• Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. *Circulation. Cardiovascular interventions*
  2019; 12 (7): e007342

• Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. *Journal of the American Heart Association*
  2018; 7 (24): e009609

• Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
  2018; 7 (24)

• Cost-Effectiveness of Alirocumab Based on Evidence From a Large Multinational Outcome Trial: The ODYSSEY OUTCOMES Economics Study
  LIPPINCOTT WILLIAMS & WILKINS.2018: E753–E754

• Alirocumab Reduces Risk of Death after Acute Coronary Syndrome in Patients with Persistently Elevated Atherogenic Lipoproteins on Intensive Statin Treatment
  LIPPINCOTT WILLIAMS & WILKINS.2018: E772–E773

• The Myheart Counts Cardiovascular Health Study: A Randomized Controlled Trial of Digital Health Coaching for Physical Activity Promotion
  Shcherbina, A., Hershman, S., King, A. C., Hekler, E., Pavlovic, A., Waggott, D., McConnell, M. V., Ashley, E. A., Harrington, R. A.
  LIPPINCOTT WILLIAMS & WILKINS.2018: E767

• Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10854 patients from the CHAMPION PHOENIX trial. *European heart journal*
• Promise and Perils of Big Data and Artificial Intelligence in Clinical Medicine and Biomedical Research  CIRCULATION RESEARCH
Rodriguez, F., Scheinker, D., Harrington, R. A.
2018; 123 (12): 1282-1284

• Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPIONPHOENIX trial  EUROPEAN HEART JOURNAL
2018; 39 (46): 4112-21

• Sex Disparities in Authorship Order of Cardiology Scientific Publications Trends Over 40 Years  CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
2018; 11 (12)

• Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial  THROMBOSIS AND HAEMOSTASIS
2018; 118 (12): 2046-2052

• Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome  NEW ENGLAND JOURNAL OF MEDICINE
2018; 379 (22): 2107-2117

• Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial.  International journal of cardiology
2018

• Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial.  Thrombosis and haemostasis
2018

• Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.  The New england journal of medicine
2018

• Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial  LIPPINCOTT WILLIAMS & WILKINS.2018
2018

• Betrixaban Reduced the Occurrence of Major Adverse Cardiovascular Events Among Acute Medically Ill Patients With a History of Myocardial Infarction or Stroke: Insights From the APEX Trial  LIPPINCOTT WILLIAMS & WILKINS.2018
2018

• Prognostic Value of C-Reactive Protein as Inflammatory Marker for Venous Thromboembolism in Acutely Ill Hospitalized Patients: Analysis From the APEX Trial  LIPPINCOTT WILLIAMS & WILKINS.2018
2018

• Hypoalbuminemia and Its Association With Venous Thromboembolism in Acutely Ill Hospitalized Patients: Findings From the APEX Trial  LIPPINCOTT WILLIAMS & WILKINS.2018
2018
• Stroke Outcomes With Vorapaxar versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
  LIPPINCOTT WILLIAMS & WILKINS.2018

• Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study
  2018; 92 (5): E348–E355

• Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials
  2018; 270: 96–101

• Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial.
  2018

• Planning and Conducting the ISCHEMIA Trial. Circulation
  Maron, D. J., Harrington, R. A., Hochman, J. S.
  2018; 138 (14): 1384-1386

• County-Level Hispanic Ethnic Density and Cardiovascular Disease Mortality
  2018; 7 (19)

• Planning and Conducting the ISCHEMIA Trial: Setting the Record Straight
  CIRCULATION
  Maron, D. J., Harrington, R. A., Hochman, J. S.
  2018; 138 (14): 1384–86

• Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry
  AmeriHeart Journ.
  2018; 204: 9–16

• Heart Centers for Women: Historical Perspective on Formation and Future Strategies to Reduce Cardiovascular Disease
  Circulation
  2018; 138 (11): 1155–65

• Heart Centers for Women. Circulation
  2018; 138 (11): 1155-1165

• Healthcare Service Utilization under a New Virtual Primary Care Delivery Model. Telemedicine journal and e-health : the official journal of the American Telemedicine Association
  2018

• Healthcare Service Utilization under a New Virtual Primary Care Delivery Model
  Telemedicine and e-health
• Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial BLOOD CELLS MOLECULES AND DISEASES
2018; 72: 37–43

• Data Sharing: The Time Has (Not Yet?) Come JAMA CARDIOLOGY
Yancy, C. W., Harrington, R. A., Bonow, R. O.
2018; 3 (9): 797–98

• Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy AMERICAN JOURNAL OF MEDICINE
2018; 131 (8): 972.e1–972.e7

• Characterization of major and clinically relevant non-major bleeding in the APEX trial
OXFORD UNIV PRESS.2018: 1264–65

• Performance of a machine learning model vs. IMPROVE score for VTE prediction in acute medically ill patients: insights from the APEX trial
OXFORD UNIV PRESS.2018: 431

• Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial
OXFORD UNIV PRESS.2018: 868

• Association of low hemoglobin with venous thromboembolism in acutely ill hospitalized medical patients: findings from the APEX trial
OXFORD UNIV PRESS.2018: 318

• Betrixaban compared to enoxaparin among obese acute medically ill subjects: an APEX trial subgroup analysis
OXFORD UNIV PRESS.2018: 7–8

• Asymptomatic deep vein thrombosis in acutely ill medical patients: insights from the APEX trial
OXFORD UNIV PRESS.2018: 31–32

• Men Versus Women. Circulation. Cardiovascular interventions
Rodriguez, F., Harrington, R. A.
2018; 11 (8): e007016

• Evaluating Health Technology Through Pragmatic Trials Novel Approaches to Generate High-Quality Evidence JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Peterson, E. D., Harrington, R. A.
2018; 320 (2): 137–38

• Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction AMERICAN HEART JOURNAL
2018; 201: 103–10

• International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design AMERICAN HEART JOURNAL
Using Digital Health Technology to Better Generate Evidence and Deliver Evidence-Based Care. *Journal of the American College of Cardiology*


2018; 71 (23): 2680–90

Mobile Health Advances in Physical Activity, Fitness, and Atrial Fibrillation Moving Hearts. *Journal of the American College of Cardiology*

McConnell, M. V., Turakhia, M. P., Harrington, R. A., King, A. C., Ashley, E. A.

2018; 71 (23): 2691–2701

Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. *International Journal of Cardiology*


2018

Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITA. *Circulation*


2018; 137 (23): 2427–29

LP(A) and Cardiovascular Outcomes: An Analysis from the Odyssey Outcomes Trial. *European Journal of Preventive Cardiology*


Elsevier Ireland Ltd. 2018: 24–25

Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. *JACC: Cardiovascular Interventions*


2018; 11 (9): e005635

The TREAT Trial—Moving ST-Elevation Myocardial Infarction Care Forward, With More to Do. *JAMA Cardiology*

Yancy, C. W., Harrington, R. A.

2018; 3 (5): 399–400

The efficacy of early versus delayed P2Y(12) inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis. *EuroIntervention*


2018; 14 (1): 78–85

International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. *American Heart Journal*


2018; 201: 124–35

Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). *Circulation. Cardiovascular Interventions*


2018; 11 (4): e005635

Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) *Circulation-Cardiovascular Interventions*
2018; 11 (4)

- Optimised care of elderly patients with acute coronary syndrome EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE
Leonardi, S., Bueno, H., Ahrens, I., Hassager, C., Bonnefoy, E., Lettino, M.
2018; 7 (3): 287–95

- Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients AMERICAN HEART JOURNAL
2018; 198: 84–90

- THE Efficacy and safety of cangrelor for patients undergoing single vessel versus multi vessel PERCUTANEOUS coronary intervention: insights from the CHAMPION PHOENIX TRIAL
ELSEVIER SCIENCE INC.2018: 29

- Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial AMERICAN HEART JOURNAL
2018; 197: 1–8

- Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials EUROINTERVENTION
2018; 13 (15): 1841–49

- Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial AMERICAN HEART JOURNAL
2018; 196: 28–35

- Improving Heart Failure Therapeutics Development in the United States The Heart Failure Collaboratory JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
2018; 71 (4): 443–53

- Canakinumab for Atherosclerotic Disease NEW ENGLAND JOURNAL OF MEDICINE
Nerlekar, N., Harper, R. W.
2018; 378 (2): 199

- Canakinumab for Atherosclerotic Disease REPLY NEW ENGLAND JOURNAL OF MEDICINE
Harrington, R. A.
2018; 378 (2): 199–200

- Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial) CIRCULATION
2018; 137 (1): 91–94

- What This Computer Needs Is a Physician Humanism and Artificial Intelligence JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Verghese, A., Shah, N. H., Harrington, R.
2018; 319 (1): 19–20

- Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial JOURNAL OF THROMBOSIS AND THROMBOLYSIS
2018; 45 (1): 1–8

- **Sex Disparities in Authorship Order of Cardiology Scientific Publications.** *Circulation. Cardiovascular quality and outcomes*
  2018; 11 (12): e005040

- **Promise and Perils of Big Data and Artificial Intelligence in Clinical Medicine and Biomedical Research.** *Circulation research*
  Rodriguez, F. n., Scheinker, D. n., Harrington, R. A.
  2018; 123 (12): 1282–84

- **Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?** *European heart journal*
  2018

- **Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial.** *TH open: companion journal to thrombosis and haemostasis*
  2018; 2 (1): e16–e24

- **Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials** *INTERNATIONAL JOURNAL OF CARDIOLOGY*
  2017; 250: 49–55

- **Resuscitating Cardiovascular Drug Development** *JAMA CARDIOLOGY*
  Helmy, K., Harrington, R. A., Kocher, B.
  2017; 2 (12): 1295–96

- **Nativity Status and Cardiovascular Disease Mortality Among Hispanic Adults** *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
  2017; 6 (12)

- **Cost-effectiveness of PCSK9 Inhibitors Proof in the Modeling** *JAMA CARDIOLOGY*
  Bonow, R. O., Harrington, R. A., Yancy, C. W.
  2017; 2 (12): 1298–99

- **Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial** *THROMBOSIS AND HAEMOSTASIS*
  2017; 117 (12): 2389–95

- **Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy** *PHARMACEUTICAL STATISTICS*
  2017; 16 (6): 445–50

- **Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX)** *AMERICAN JOURNAL OF CARDIOLOGY*
  2017; 120 (7): 1043–48

- **Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention Findings From CHAMPION PHOENIX** *CIRCULATION-CARDIOVASCULAR INTERVENTIONS*
  2017; 10 (8)
• Genetic variability in PAR4 platelet response in relation to bleeding and ischemic outcomes: a genetic substudy of the TRACER trial
  OXFORD UNIV PRESS.2017: 646

• The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis
  OXFORD UNIV PRESS.2017: 1263-1264

• History of venous thromboembolism is associated with higher risk for recurrent venous thromboembolism: insights from the APEX trial
  OXFORD UNIV PRESS.2017: 1205

• N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with stroke among hospitalized medical patients: an APEX trial substudy
  OXFORD UNIV PRESS.2017: 886

• D-dimer concentration is associated with increased risk for VTE and greater absolute benefit of extended prophylaxis with betrixaban in acutely III medical patients: insights from the APEX trial
  OXFORD UNIV PRESS.2017: 326

• Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis
  OXFORD UNIV PRESS.2017: 1204–5

• Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy
  OXFORD UNIV PRESS.2017: 382

• Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely III Medical Patients: An APEX Trial Substudy JOURNAL OF THE AMERICAN HEART ASSOCIATION
  2017; 6 (7)

• Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. American heart journal
  2017; 184: 147-155

• Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery NEW ENGLAND JOURNAL OF MEDICINE
  2017; 376 (21): 2032–42

• Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. American heart journal
  2017; 187: 194-203

• Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
  2017; 69 (14): 1861-1870
• Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. *The American journal of medicine*
2017

• New Delivery Model for Rising-Risk Patients: The Forgotten Lot? *Telemedicine journal and e-health*
Cheung, L., Norden, J., Harrington, R. A., Desai, S. A.
2017

• Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from *EARLY ACS INTERNATIONAL JOURNAL OF CARDIOLOGY*
2017; 232: 264–70

• Potent P2Y(12) Inhibitors in Men Versus Women A Collaborative Meta-Analysis of Randomized Trials *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
2017; 69 (12): 1549-1559

• Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. *Journal of the American College of Cardiology*
2017; 69 (12): 1549-1559

• NATIVITY STATUS AND CARDIOVASCULAR DISEASE MORTALITY AMONG HISPANICS
Rodriguez, F., Hastings, K., Hu, J., Harrington, R., Palaniappan, L.
ELSEVIER SCIENCE INC.2017: 1753

• ONE-YEAR MORTALITY INCREASED IN PATIENTS WITH PERI-PROCEDURAL MYOCARDIAL INFARCTION: INSIGHTS FROM THE CHAMPION TRIALS
ELSEVIER SCIENCE INC.2017: 7

• IMPACT OF PERIPROCEDURAL MYOCARDIAL INFARCTION IN CONTEMPORARY PCI: POOLED PATIENT-LEVEL DATA FROM THE CHAMPION TRIALS
ELSEVIER SCIENCE INC.2017: 112

• CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF UNFRACTIONATED HEPARIN INSIGHTS FROM CHAMPION PHOENIX
ELSEVIER SCIENCE INC.2017: 1345

• Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial *EUROPEAN HEART JOURNAL*
2017; 38 (11): 804-?

• The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. *American heart journal*
2017; 185: 93-100

• Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). *Circulation*
2017; 135 (7): 648-655
• Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. *Clinical Chemistry*
  2017; 63 (2): 573-584

• Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. *JAMA Cardiology*
  2017; 2 (2): 127-135

• Disaggregation of Cause-Specific Cardiovascular Disease Mortality Among Hispanic Subgroups. *JAMA Cardiology*
  2017

• Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. *Journal of the American College of Cardiology*
  2017; 69 (2): 176-185

• The Systematic Evaluation of Identifying the Infarct Related Artery Utilizing Cardiac Magnetic Resonance in Patients Presenting with ST-Elevation Myocardial Infarction. *PLOS One*
  2017; 12 (1)

• Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. *Circulation-Cardiovascular Interventions*
  2017; 10 (1)

• Author Relationships With Industry: Policies and Procedures for Authors and Editors of JAMA Cardiology. *JAMA Cardiology*
  Yancy, C. W., Harrington, R. A., Bonow, R. O.
  2017; 2 (11): 1181–82

• Feasibility of Obtaining Measures of Lifestyle From a Smartphone App: The MyHeart Counts Cardiovascular Health Study. *JAMA Cardiology*
  2017; 2 (1): 67-76

• The Academic Medical System: Reinvention to Survive the Revolution in Health Care. *Journal of the American College of Cardiology*
  2017; 69 (10): 1305–12

• Bleeding and Mortality With Dual Antiplatelet Therapy: The Rashomon Effect. *Journal of the American College of Cardiology*
  Rao, S. V., Harrington, R. A.
  2017; 69 (16): 2023–25

• When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. *American Heart Journal*
  2017; 189: 1–8

• Unreliable Observations from a Confounded Analysis of a Skewed Database. *The American Journal of Medicine*
  2017; 130 (8): e355–e356

• Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. *International Journal of Cardiology*

---

Robert Harrington
http://cap.stanford.edu/profiles/Robert_Harrington/
2017; 245: 271–76

- Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. *Journal of thrombosis and haemostasis: JTH*

- Targeting Inflammation in Coronary Artery Disease. *The New England journal of medicine*
Harrington, R. A. 2017; 377 (12): 1197–98

- N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. *Journal of thrombosis and thrombolysis*

- The IMPROVED VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. *TH open: companion journal to thrombosis and haemostasis*

- Nativity Status and Cardiovascular Disease Mortality Among Hispanic Adults. *Journal of the American Heart Association*

- The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human APOA-I, After Acute Myocardial Infarction - The APOA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial
LIPPINCOTT WILLIAMS & WILKINS.2016: E706

- Betrixaban in Acutely Ill Medical Patients Reply. *NEW ENGLAND JOURNAL OF MEDICINE*

- Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I) *CIRCULATION*
2016; 134 (24): 1918-?

2016; 134 (24): 1918-1930

- The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial
AMER SOC HEMATOLOGY.2016

- Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial*AMERICAN HEART JOURNAL*
Radial access in patients with acute coronary syndrome without persistent ST-segment elevation: Systematic review, collaborative meta-analysis, and meta-regression *INTERNATIONAL JOURNAL OF CARDIOLOGY*


2016; 222: 1031-1039

The State of Medical Student Performance Evaluations: Improved Transparency or Continued Obfuscation? *ACADEMIC MEDICINE*

Hom, J., Richman, I., Hall, P., Ahuja, N., Harman, S., Harrington, R., Witteles, R.

2016; 91 (11): 1534–39

The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*


2016; 68 (17): 1898-1907

Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction *AMERICAN HEART JOURNAL*


2016; 180: 22-28

The Outlook of Digital Health for Cardiovascular Medicine: Challenges but Also Extraordinary Opportunities. *JAMA cardiology*

Turakhia, M. P., Desai, S. A., Harrington, R. A.

2016; 1 (7): 743-744

Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention The CHAMPION PHOENIX Trial *JACC-CARDIOVASCULAR INTERVENTIONS*


2016; 9 (18): 1905-1913

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). *Circulation*


2016; 134 (10): 723-733

A resident-created hospitalist curriculum for internal medicine housestaff. *Journal of hospital medicine*

Kumar, A., Smeraglio, A., Witteles, R., Harman, S., Nallamshetty, S., Rogers, A., Harrington, R., Ahuja, N.

2016; 11 (9): 646-649

Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. *New England journal of medicine*


2016; 375 (6): 534-544

Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. *European heart journal. Acute cardiovascular care*


2016

Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. *American heart journal*


2016; 178: 176-184
Does a clinical history of gout influence the relationship of serum uric acid levels and cardiovascular outcomes among patients with acute coronary syndromes?
OXFORD UNIV PRESS.2016: 458

Radial access in patients with acute coronary syndromes without persistent ST-segment elevation: meta-analysis, and meta-regression
OXFORD UNIV PRESS.2016: 579

Bleeding events and subsequent 30-day and 1-year mortality after percutaneous coronary intervention: a contemporary pooled patient-level analysis from the CHAMPION trials
OXFORD UNIV PRESS.2016: 614

Off hours versus on hours presentation in ST-segment elevation myocardial infarction: findings from CHAMPION PHOENIX
OXFORD UNIV PRESS.2016: 1175-1176

Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials
OXFORD UNIV PRESS.2016: 1233

Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. Catheterization and cardiovascular interventions
2016; 88 (2): 163-173

Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. American heart journal
2016; 178: 1-8

Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial AMERICAN HEART JOURNAL
2016; 177: 1-8

Defining a Mobile Health Roadmap for Cardiovascular Health and Disease. Journal of the American Heart Association
2016; 5 (7)

Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes The TRACER Trial JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis Results From the TRACER Angiographic Substudy  CIRCULATION-CARDIOVASCULAR INTERVENTIONS
2016; 9 (5)

VTE Prevention in Acutely Ill Medical Patients with Extended Duration Betrixaban - A Multicenter, Randomized, Active-Controlled Efficacy and Safety Study Comparing Extended Duration Betrixaban with Standard of Care Enoxaparin
WILEY-BLACKWELL.2016: 8–9

Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need  JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
2016; 21 (3): 227-232

Tooth loss is independently associated with poor outcomes in stable coronary heart disease  EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
2016; 23 (8): 839-846

Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials  CIRCULATION
2016; 133 (16): 1560-7

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX  EUROPEAN HEART JOURNAL
2016; 37 (14): 1122-1130

THE EFFICACY AND SAFETY OF CANGRELOR WITH AND WITHOUT GLYCOPROTEIN IIb/IIIa INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POOLED ANALYSIS OF THE CHAMPION TRIALS

Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention  HEART
2016; 102 (8): 617-625

Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.  Heart (British Cardiac Society)
2016; 102 (8): 617-25

Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome.  JAMA cardiology
2016; 1 (1): 73-79

Coronary Artery Bypass Surgery Is Not Underutilized!  CIRCULATION
Fearon, W. F., Harrington, R. A.
2016; 133 (10): 1027–35

Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.  European heart journal. Acute cardiovascular care


Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. *International Journal of Cardiology* 2016; 203: 708-713

Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. *Circulation* 2016; 133 (2): 131-138

Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. *Circulation* 2016; 133 (2): 131-8


Response to Letters Regarding Article, "Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial". *Circulation* 2016; 133 (21): e665

• Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering. *JAMA*
  Rodriguez, F. n., Harrington, R. A.

• High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction *AMERICAN HEART JOURNAL*
  2016; 171 (1): 25-32

• Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape A Conference Report From the American Heart Association Data Summit 2015 *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
  2015; 4 (11)

• Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial *EUROINTERVENTION*
  2015; 11 (7): 737-745

• Team-Based Care and Quality A Move Toward Evidence-Based Policy *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
  Harrington, R. A., Heidenreich, P. A.
  2015; 66 (16): 1813–15

• Efficacy of Cangrelor in Lesions with High-Risk and Low-Risk Angiographic Characteristics: The CHAMPION PHOENIX trial
  ELSEVIER SCIENCE INC.2015: B36–B37

• Cangrelor Improves Ischemic Outcomes In Patients With Multivessel Disease And Single Vessel Disease Undergoing PCI: Insights From The CHAMPION PHOENIX Trial
  ELSEVIER SCIENCE INC.2015: B35

• Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials *JOURNAL OF THROMBOSIS AND THROMBOLYSIS*
  2015; 40 (3): 317-322

• Clinician Innovator: A Novel Career Path in Academic Medicine A Presidentially Commissioned Article From the American Heart Association *JOURNAL OF THE AMERICAN HEART ASSOCIATION*
  2015; 4 (10)

• Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome *HEART*
  2015; 101 (18): 1475-1484

• Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life substudy *AMERICAN HEART JOURNAL*
  2015; 170 (2): 371-379

• Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study
  OXFORD UNIV PRESS.2015: 237
• The effect of cangrelor and access site on ischemic and bleeding events: insights from CHAMPION-PHOENIX
  OXFORD UNIV PRESS.2015: 681

• Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: the CHAMPION experience
  OXFORD UNIV PRESS.2015: 698

• Living alone and depressive symptoms are associated with major cardiovascular events in patients with chronic coronary heart disease
  OXFORD UNIV PRESS.2015: 1144

• Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life substudy. American heart journal
  2015; 170 (2): 371-379

• Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients Insights From Clinical Trials Over 17 Years CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
  2015; 8 (4): 357-367

• The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations AMERICAN HEART JOURNAL
  2015; 169 (6): 743-750

• Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. Circulation. Cardiovascular interventions
  2015; 8 (6)

• Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes JOURNAL OF THE AMERICAN HEART ASSOCIATION
  2015; 4 (6)

• Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial) AMERICAN JOURNAL OF CARDIOLOGY
2015; 115 (10): 1325-1332

Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). American journal of cardiology
2015; 115 (10): 1325-1332

COCATS 4 Task Force 15: Training in Cardiovascular Research and Scholarly Activity JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
2015; 65 (17): 1899-1906

Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for Prevention of Acute Ischemic Events 2 trial AMERICAN HEART JOURNAL
2015; 169 (4): 531-538

Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for Prevention of Acute Ischemic Events 2 trial. American heart journal
2015; 169 (4): 531-538

Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin Insights From the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]) JACC-CARDIOVASCULAR INTERVENTIONS
2015; 8 (3): 424-433

Economic Analysis of Ticagrelor Therapy From a US Perspective JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
2015; 65 (5): 465-476

Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. Journal of the American College of Cardiology
2015; 65 (5): 465-76

More Than 10 Million Steps in the Right Direction: Results From the First American Heart Association Scientific Sessions Walking Challenge PROGRESS IN CARDIOVASCULAR DISEASES
Harrington, R. A., Arena, R., Despres, J., Ciarochi, A., Croll, E., Bloch, K. D.
2015; 57 (4): 296-298

Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. American heart journal
2015; 169 (1): 186-187

Harrington, R. A.
2015; 372 (13): 1261–63

Appropriate Use Criteria for Coronary Revascularization and the Learning Health System: A Good Start. JAMA
Harrington, R. A.
2015; 314 (19): 2029–31

Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. Journal of the American Heart Association
2015; 4 (12)

D-Dimer elevation and adverse outcomes JOURNAL OF THROMBOSIS AND THROMBOLYSIS
2015; 39 (1): 55-59

Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial AMERICAN HEART JOURNAL
2014; 168 (6): 869-?

Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. American heart journal
2014; 168 (6): 869-77.e1

Predictors of contemporary coronary artery bypass grafting outcomes JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
2014; 148 (6): 2720-U1368

Extent, Location, and Clinical Significance ? of Non-Infarct-Related Coronary Artery Disease Among Patients With ST-Elevation Myocardial Infarction JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
2014; 312 (19): 2019-2027

Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA
2014; 312 (19): 2019-27

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial AMERICAN HEART JOURNAL
2014; 168 (5): 682-689

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. American heart journal
2014; 168 (5): 682-9

Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) AMERICAN HEART JOURNAL
2014; 168 (4): 588-596

Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). American heart journal
2014; 168 (4): 588-96

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX
ELSEVIER SCIENCE INC.2014: B142

- Usefulness and Safety of Vorapaxar in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial). American journal of cardiology
2014; 114 (5): 665-673

- Prognostic implications of major bleeding on mortality in ACS patients. An analysis of the PLATO trial
OXFORD UNIV PRESS.2014: 136

- Early benefit of cangrelor in patients undergoing PCI in CHAMPION PHOENIX
OXFORD UNIV PRESS.2014: 1031

- No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: Challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of CARDIOLOGY
2014; 176 (1): 300-302

- Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. European heart journal. Acute cardiovascular care
2014; 3 (3): 246-256

- Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial EUROPEAN HEART JOURNAL
2014; 35 (31): 2083-2093

- Vein Graft Preservation Solutions, Patency, and Outcomes After Coronary Artery Bypass Graft Surgery Follow-up From PREVENT IV Randomized Clinical Trial JAMA SURGERY
2014; 149 (8): 798-805

- A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention The SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) Trial JACC-CARDIOVASCULAR INTERVENTIONS
2014; 7 (8): 857-867

- Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non-ST-segment elevation acute coronary syndromes AMERICAN HEART JOURNAL
2014; 168 (2): 182-?

- A ‘green button’ for using aggregate patient data at the point of care. Health affairs
2014; 33 (7): 1229-1235
- Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value. *Thrombosis and Haemostasis*
  2014; 112 (1): 12-14

- Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes. *Circulation Research*
  Bhatt, D. L., Hulot, J., Moliterno, D. J., Harrington, R. A.
  2014; 114 (12): 1929-1943

- Comparison of Clinical Trial Outcome Patterns in Patients Following Acute Coronary Syndromes and in Patients With Chronic Stable Atherosclerosis. *Clinical Cardiology*
  2014; 37 (6): 337-342

- Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis. *Clinical cardiology*
  2014; 37 (6): 337-342

- Response to Letter Regarding Article, "Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial". *Circulation*
  2014; 129 (19): E494-E495

- Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. *Thrombosis and Haemostasis*
  2014; 111 (5): 883-891

- Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. *New England Journal of Medicine*
  2014; 370 (18): 1702-1711

- Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial. *Journal of the American College of Cardiology*
  2014; 63 (15): 1493-1499

- Angiographic Outcomes With Early Eptifibatide Therapy in Non-ST-Segment Elevation Acute Coronary Syndrome (from the EARLY ACS Trial). *American Journal of Cardiology*
  2014; 113 (8): 1297-1305

- Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. *Nephrology Dialysis Transplantation*
  2014; 29 (4): 833-842

- Reduced Death, Myocardial Infarction, and Early Stent Thrombosis With Cangrelor Versus Clopidogrel on a Background of Bivalirudin: Insights From Champion Phoenix.
  ELSEVIER SCIENCE INC.2014: A36

- Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery: Subgroup Analysis From the TRACER Trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). *Journal of the American College of Cardiology*
• Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery. *Journal of the American College of Cardiology*
  2014; 63 (11): 1048-1057

• Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial). *American Journal of Cardiology*
  2014; 113 (6): 936-944

• The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. *American Heart Journal*
  2014; 167 (3): 335-341

• Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. *European Heart Journal-Acute Cardiovascular Care*
  2014; 3 (1): 37-45

• Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention: Insights From the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). *Journal of the American College of Cardiology*
  2014; 63 (7): 619-629

• Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention. *Journal of the American College of Cardiology*
  2014; 63 (7): 619-629

• A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. *Transfusion*
  2014; 54 (2): 306-315

• Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial. *Circulation*
  2014; 129 (3): 293-303

  2014; 170 (3): e59-62

• From abstract to peer-reviewed publication: country matters. *International Journal of Cardiology*
  2014; 174 (3): 830–32

• Advances in understanding percutaneous coronary intervention pharmacology: ischemia, bleeding, the ISAR research group, and a commitment to progress. *Coronary artery disease*
Harrington, R. A., Popma, C. J., Gibson, C. M.

• Calculating risks and benefits to help guide revascularization decisions: turning all available data into useful information. Journal of the American College of Cardiology
Harrington, R. A.
2014; 64 (5): 433–35

• A message from modern-day healthcare to physical activity and fitness: welcome home! Progress in cardiovascular diseases
Arena, R. n., Harrington, R. A., Després, J. P.
2014; 57 (4): 293–95

• Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data LANCET

• Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Peripheral Artery Disease: Results From TRACER
LIPPINCOTT WILLIAMS & WILKINS.2013

• Preservation Solutions, Patency, and Outcomes After Coronary Bypass Surgery
LIPPINCOTT WILLIAMS & WILKINS.2013

• Fasting Glucose, NT-proBNP, Treatment With Glycoprotein IIb/IIIa Inhibitors, and Outcomes in Non-ST-Segment Elevation Acute Coronary Syndromes: An Analysis From EARLY ACS
LIPPINCOTT WILLIAMS & WILKINS.2013

• Trends in Enrollment, Patient Characteristics, Treatments and Outcomes of Older Adults With Non-ST-segment Elevation Acute Coronary Syndromes (ACS) in Clinical Trials
LIPPINCOTT WILLIAMS & WILKINS.2013

• Arterial Access Site and Outcomes in Patients Undergoing Percutaneous Coronary Intervention With and Without Vorapaxar
LIPPINCOTT WILLIAMS & WILKINS.2013

• Efficacy and Safety of Vorapaxar in Elderly Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Insights From the TRACER Trial
LIPPINCOTT WILLIAMS & WILKINS.2013

• Differential Prognostic Implications of Peak Troponin Level in Acute Coronary Syndrome Treated With and Without Revascularization
LIPPINCOTT WILLIAMS & WILKINS.2013

• Evolution of Differences in Women and Men With Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From Clinical Trials Over 15 Years
LIPPINCOTT WILLIAMS & WILKINS.2013

• CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS: Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial
LIPPINCOTT WILLIAMS & WILKINS.2013
• Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. *Journal of Thrombosis and Thrombolysis*


2013; 36 (4): 384-393

• Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: Insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. *American Heart Journal*


2013; 166 (4): 723-728

• Outcomes with ticagrelor versus clopidogrel in relation to high sensitivity troponin-T in non-ST-elevation acute coronary syndrome patients managed with early invasive or non-invasive treatment - a substudy from the prospective randomized PLATElet inhibit


Wiley-Blackwell. 2013: E189

• Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial. *International Journal of Cardiology*


2013; 167 (6): 2580-2587

• Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial. *Circulation*


2013; 128 (10): 1055-1065

• A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. *Heart*


2013; 99 (17): 1282-1287

• Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. *European Heart Journal: Acute Cardiovascular Care*


2013; 2 (3): 246-255

• Routine early ticagrelor versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndrome patients: An analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. *American Heart Journal*


2013; 166 (3): 466-7

• Quantitative ST-depression in Acute Coronary Syndromes: the PLATO Electrocardiographic Substudy. *American Journal of Medicine*


2013; 126 (8): 723-7

• Intracranial hemorrhage in acute coronary syndrome: incidence, predictors, and outcomes from APPRAISE-2, PLATO, and TRACER


Oxford University Press. 2013: 23

• From abstract to peer-reviewed publication: country matters


Oxford University Press. 2013: 476

• Relationship between diabetes, race, obesity and outcomes in patients with acute coronary syndrome: a pool analysis from randomized trials

International variation in management and outcomes in high-risk patients following acute coronary syndromes: results from the APPRAISE-2 trial
OXFORD UNIV PRESS.2013: 885

Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years INTERNATIONAL JOURNAL OF CARDIOLOGY
2013; 167 (2): 548-554

Platelet inhibition with cangrelor during PCI. The New England journal of medicine
Bhatt, D. L., Harrington, R. A.
2013; 369 (4): 393-4

Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non-ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker Trends JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
2013; 62 (3): 242-251

Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes) JACC-CARDIOVASCULAR INTERVENTIONS
2013; 6 (7): 671-683

Assessing Research Results in the Medical Literature Trust but Verify JAMA INTERNAL MEDICINE
Califf, R. M., McCall, J., Harrington, R. A.
2013; 173 (12): 1053-1055

2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Critical pathways in cardiology
2013; 12 (2): 65-105

Heart Failure Complicating Non-ST-Segment Elevation Acute Coronary Syndrome Timing, Predictors, and Clinical Outcomes JACC-HEART FAILURE
2013; 1 (3): 223-229

Heart Failure Complicating Non-ST-Segment Elevation Acute Coronary Syndrome: Timing, Predictors, and Clinical Outcomes JACC. Heart failure
2013; 1 (3): 223-229

Rescuing clinical trials in the United States and beyond: A call for action AMERICAN HEART JOURNAL
2013; 165 (6): 837-847

A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: Design of the RENEW study AMERICAN HEART JOURNAL
2013; 165 (6): 854-7

Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome AMERICAN HEART JOURNAL
• Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA.CER) trial. *EUROPEAN HEART JOURNAL*
2013; 34 (23): 1723-1731

• Response to letter regarding article, “sustained ventricular tachycardia and ventricular fibrillation complicating non–ST-segment elevation acute coronary syndromes”. *Circulation*
2013; 127 (20): e634

• Ticagrelor in Patients With Acute Coronary Syndromes and Stroke Interpretation of Subgroups in Clinical Trials. *STROKE*
2013; 44 (5): 1477-1479

• Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. *NEW ENGLAND JOURNAL OF MEDICINE*
2013; 368 (14): 1303-1313

• Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. *Journal of thrombosis and thrombolysis*
2013

• Left Bundle Branch Block in Non-ST-Segment Elevation Acute Coronary Syndromes Incidence, Angiographic Characteristics, and Clinical Outcomes. *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
2013; 61 (13): 1461-1463

• Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. *AMERICAN HEART JOURNAL*
2013; 165 (4): 583-?

• Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. *JOURNAL OF THROMBOSIS AND HAEMOSTASIS*
2013; 11 (4): 778-782

• ACP Journal Club. PCI using drug-eluting stents had higher mortality than CABG in diabetes and multivessel CAD. *Annals of internal medicine*
Harrington, R. A.
2013; 158 (6): JC8-?

• 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). *Circulation*
2013; 127 (9): 1052-1089

• 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards). *Journal of the American College of Cardiology*
Response to letter regarding article, "ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". Stroke; a journal of cerebral circulation
2013; 44 (8): e95–6

ACP Journal Club. Intraaortic balloon counterpulsation did not reduce mortality in acute MI with cardiogenic shock. Annals of internal medicine
Harrington, R. A.
2012; 157 (12): JC6-11

Conversion of Cardiovascular Conference Abstracts to Publications CIRCULATION
2012; 126 (24): 2819-7

2012; 87 (12): 1710-1714

EPC Mobilization After Erythropoietin Treatment in Acute St-elevation Myocardial Infarction: The Reveal EPC Substudy
LIPPINCOTT WILLIAMS & WILKINS 2012

Cardiac Biomarker Elevation during Stem Cell Mobilisation, Apheresis and Intramyocardial Delivery is Common but does not Impact Incidence of Long-Term MACE: An Analysis from ACT34-CMI
LIPPINCOTT WILLIAMS & WILKINS 2012

A Phase 3, Randomized, Partially Blinded, Active-Controlled, Study Assessing the Efficacy and Safety of Intramyocardial Autologous CD34+Cell Administration in Patients with Refractory Angina: Design of the RENEW Study
LIPPINCOTT WILLIAMS & WILKINS 2012

Transforming Clinical Trials in Cardiovascular Disease Mission Critical for Health and Economic Well-being JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Antman, E. M., Harrington, R. A.
2012; 308 (17): 1743-1744

Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: An analysis from ACT34-CMI AMERICAN HEART JOURNAL
2012; 164 (5): 689-U86

Road mapping ATLAS ACS 2: are we there yet? EUROPEAN HEART JOURNAL
Armstrong, P. W., Harrington, R. A.
2012; 33 (20): 2510-2512

Association Between Angiographic Complications and Clinical Outcomes Among Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention An EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) Angiographic Substudy JACC-CARDIOVASCULAR INTERVENTIONS
2012; 5 (9): 927-935

2012; 80 (3): E37-49
• Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results \textit{AMERICAN HEART JOURNAL}
2012; 164 (3): 379-U284

• Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial \textit{AMERICAN HEART JOURNAL}
2012; 164 (3): 334-U239

• 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. \textit{journal of thoracic and cardiovascular surgery}
2012; 144 (3): e29-84

• Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? proceedings of an ad hoc working group meeting. \textit{Journal of thrombosis and haemostasis : JTH}
2012

• Lecture Halls without Lectures \textit{NEW ENGLAND JOURNAL OF MEDICINE}
2012; 367 (7): 678-678

• Effect of Adenosine-Regulating Agent Acadesine on Morbidity and Mortality Associated With Coronary Artery Bypass Grafting The RED-CABG Randomized Controlled Trial \textit{JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION}
2012; 308 (2): 157-164

• Usefulness of Medical Conferences \textit{JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION}
Antman, E. M., Harrington, R., Tomaselli, G.
2012; 308 (1): 31-32

• Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non-ST-Segment-Elevation Acute Coronary Syndromes \textit{CIRCULATION}
2012; 126 (1): 41-49

• Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil \textit{JOURNAL OF THROMBOSIS AND THROMBOLYSIS}
2012; 34 (1): 143-163

• Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials \textit{JOURNAL OF THROMBOSIS AND THROMBOLYSIS}
2012; 34 (1): 44-55

• 2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement Developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for CardioThoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance \textit{CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS}
Pharmacokinetic and Pharmacodynamic Effects of Elinogrel Results of the Platelet Function Substudy From the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention Patients (INNOVATE-PCI) Trial


2012; 79 (7): 1023-1082

A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y(12) Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention The INNOVATE-PCI Trial


2012; 5 (3): 336-346

Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition PHOENIX trial


2012; 163 (5): 768-?

Regional Patterns of Use of a Medical Management Strategy for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Insights From the EARLY ACS Trial


2012; 5 (2): 205-213

Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor Insights From the Platelet Inhibition and Patient Outcomes Trial


2012; 125 (8): 978-986

Relationship Between Vein Graft Failure and Subsequent Clinical Outcomes After Coronary Artery Bypass Surgery


2012; 125 (6): 749-756

Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction


2012; 163 (2): 182-U275

ST-Elevation Acute Coronary Syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) Trial Insights From the ECG Substudy


2012; 125 (3): 514-U131

Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes


2012; 366 (1): 20-33

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial


2011; 32 (23): 2933-2944

Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function Substudy)

AMERICAN JOURNAL OF CARDIOLOGY
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes *EUROPEAN HEART JOURNAL*

2011; 108 (11): 1542-1546

Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function *AMERICAN HEART JOURNAL*

2011; 162 (5)

Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome *NEW ENGLAND JOURNAL OF MEDICINE*

2011; 365 (8): 699-708

Biomedical Innovation: A Risky Business at Risk *SCIENCE TRANSLATIONAL MEDICINE*

Stack, R. S., Harrington, R. A.
2011; 3 (96)

American Industry and the U.S. Cardiovascular Clinical Research Enterprise An Appropriate Analogy? *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*

Califf, R. M., Harrington, R. A.
2011; 58 (7): 677-680

Intramyocardial, Autologous CD34+Cell Therapy for Refractory Angina *CIRCULATION RESEARCH*

2011; 109 (4): 428-U235

Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial *CIRCULATION*

2011; 124 (5): 544-U78

Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, Sao Paulo, Brazil *JOURNAL OF THROMBOSIS AND THROMBOLYSIS*

2011; 32 (2): 242-266

Saphenous Vein Grafts With Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery One-Year Graft Failure and Five-Year Outcomes From the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial *CIRCULATION*

2011; 124 (3): 280-288

Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design *JOURNAL OF THROMBOSIS AND THROMBOLYSIS*

2011; 32 (1): 21-31

Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes A Systematic Overview of Randomized Clinical Trials *CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES*

2011; 4 (4): 448-458
• Dueling Registries? An Alternative Perspective and the Case for Competitive Collaboration  
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES  
Harrington, R. A.  
2011; 4 (4): 486-487

JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION  
2011; 5 (4): 259-352

• Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATElet inhibition and patient Outcomes (PLATO) trial  
BRITISH MEDICAL JOURNAL  
2011; 342

CIRCULATION  
2011; 123 (21): 2434-2506

• Intravenous Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction REVEAL: A Randomized Controlled Trial  
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION  
2011; 305 (18): 1863-1872

• The Incidence of Bradycardiacs and Clinical Bradycardiac Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial Results of the Continuous Electrocardiographic Assessment Substudy  
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY  
2011; 57 (19): 1908-1916

• The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. ”Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified” (Thromb Haemost 2011; 105.5).  
Thrombosis and haemostasis  
Wallentin, L., Becker, R. C., James, S. K., Harrington, R. A.  
2011; 105 (5): 760-762

• Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome An Analysis From the Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) Trial  
CIRCULATION  
2011; 123 (7): 722-730

• Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial  
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY  
2011; 57 (6): 672-684

• Impact of Recovery of Renal Function on Long-Term Mortality After Coronary Artery Bypass Grafting  
AMERICAN JOURNAL OF CARDIOLOGY  
2010; 106 (12): 1728-1734

• Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: A pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY  
AMERICAN HEART JOURNAL  
• Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis CIRCULATION
  2010; 122 (21): 2131-2141

• Randomized, Double-Blind, Placebo-Controlled Trial of Autologous CD34+Cell Therapy for Refractory Angina: 2-Year Safety Analysis
  LIPPINCOTT WILLIAMS & WILKINS 2010

• ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. Journal of the American College of Cardiology
  2010; 56 (22): 1864-1894

• Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial AMERICAN HEART JOURNAL
  2010; 160 (5): 795-U39

• Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome THROMBOSIS AND HAEMOSTASIS
  2010; 104 (5): 976-983

• Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease AMERICAN HEART JOURNAL
  2010; 160 (4): 655-U289

• Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from SYNERGY INTERNATIONAL JOURNAL OF CARDIOLOGY
  2010; 144 (1): 36-41

• Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial CIRCULATION
  2010; 122 (11): 1056-1067

• President’s page: the ACC reconfirms commitment to transparent relationships with industry. Journal of the American College of Cardiology
  Brindis, R., Harrington, R.
  2010; 56 (11): 900-902

• First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention CIRCULATION
  2010; 122 (6): 614-622
• Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI) AMERICAN HEART JOURNAL
2010; 160 (1): 65-72

• Randomized Evaluation of efficacy and safety of ferric carboxymaltose in Patients with iron deficiency Anaemia and Impaired Renal function (REPAIR-IDA): rationale and study design NEPHROLOGY DIALYSIS TRANSPLANTATION
2010; 25 (7): 2368-2375

• There Is a Role for Industry-Sponsored Education in Cardiology CIRCULATION
Harrington, R. A., Califf, R. M.
2010; 121 (20): 2221-2227

• An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design AMERICAN HEART JOURNAL
2010; 159 (5): 705-709

• Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel CLINICAL CARDIOLOGY
Husted, S., Storey, R. F., Harrington, R. A., Emanuelsson, H., Cannon, C. P.
2010; 33 (4): 206-212

• Towards a new order in cardiovascular medicine: re-engineering through global collaboration EUROPEAN HEART JOURNAL
2010; 31 (8): 911-917

• Metabolic Syndrome Is Not Associated With Increased Mortality or Cardiovascular Risk in Nondiabetic Patients With a New Diagnosis of Coronary Artery Disease CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
Petersen, J. L., Yow, E., Aljaroudi, W., Shaw, L. K., Goyal, A., McGuire, D. K., Peterson, E. D., Harrington, R. A.
2010; 3 (2): 165-172

• Warfarin Use and Outcomes in Patients with Atrial Fibrillation Complicating Acute Coronary Syndromes AMERICAN JOURNAL OF MEDICINE
2010; 123 (2): 134-140

• Comparison of ticagrelor with clopidogrel in patients with planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study LANCET
2010; 375 (9711): 283-293

• Intravenous Platelet Blockade with Cangrelor during PCI. NEW ENGLAND JOURNAL OF MEDICINE
2009; 361 (24): 2330-2341

• Platelet Inhibition with Cangrelor in Patients Undergoing PCI. NEW ENGLAND JOURNAL OF MEDICINE
2009; 361 (24): 2318-2329

• Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial AMERICAN HEART JOURNAL
Berger, J. S., Roe, M. T., Gibson, C. M., Kilaru, R., Green, C. L., Melton, L., Blankenship, J. D., Metzger, D. C., Granger, C. B., Gretler, D. D., Grines, C. L., Huber, K., Zeymer, et al
2009; 158 (6): 998-U145
• Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group *AMERICAN HEART JOURNAL*
  2009; 158 (6): 881-U16

• Comparison of Site-Reported and Core Laboratory-Reported Creatine Kinase-MB Values in Non-ST-Segment Elevation Acute Coronary Syndrome (from the International TRIAL SYNERGY) *AMERICAN JOURNAL OF CARDIOLOGY*
  2009; 104 (10): 1330-1335

• Autologous CD34+Cell Therapy for Refractory Angina: 12 Month Results of the Phase II ACT34-CMI Study 82nd National Conference and Exhibitions and Scientific Sessions of the American-Heart-Association
  LIPPINCOTT WILLIAMS & WILKINS.2009: S1132–S1132

• Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention 1-Year Results From the STEEPLE (SafeTy and Efficacy of Enoxaparin in Percutaneous coronary intervention patients, an international randomized Evaluation) Trial *JACC-CARDIOVASCULAR INTERVENTIONS*
  2009; 2 (11): 1083-1091

• Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PReject of Ex-vivo Vein graft ENgineering via Transsection IV (PREVENT-IV) Trial *AMERICAN HEART JOURNAL*
  2009; 158 (5): 792-798

• Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs *JOURNAL OF THROMBOSIS AND THROMBOLYSIS*
  2009; 28 (3): 366-380

• Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes *NEW ENGLAND JOURNAL OF MEDICINE*
  2009; 361 (11): 1045-1057

• Antithrombotics in Acute Coronary Syndromes *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
  2009; 54 (11): 969-984

• The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial: study design and rationale *AMERICAN HEART JOURNAL*
  2009; 158 (3): 327-U5

• Sex Differences in Mortality Following Acute Coronary Syndromes *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
  2009; 302 (8): 874-882

• Premature Release of Data from Clinical Trials of Ezetimibe *NEW ENGLAND JOURNAL OF MEDICINE*
  Califf, R. M., Harrington, R. A., Blazing, M. A.
  2009; 361 (7): 712-717

• Endoscopic versus Open Vein-Graft Harvesting in Coronary-Artery Bypass Surgery *NEW ENGLAND JOURNAL OF MEDICINE*
- A new generation of antiplatelet agents CURRENT OPINION IN CARDIOLOGY
  Sellers, M. B., Tricoci, P., Harrington, R. A.
  2009; 24 (4): 307-312

- Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial CIRCULATION
  2009; 119 (22): 2877-U39

- Careers for Clinician Investigators CIRCULATION
  Harrington, R. A., Califf, R. M., Hodgson, P. K., Peterson, E. D., Roe, M. T., Mark, D. B.
  2009; 119 (22): 2945-2950

- Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes NEW ENGLAND JOURNAL OF MEDICINE
  2009; 360 (21): 2176-2190

- Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes EUROPEAN HEART JOURNAL
  2009; 30 (10): 1195-1202

- Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography AMERICAN HEART JOURNAL
  2009; 157 (4): 716-723

- Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLAtelet inhibition and patient Outcomes (PLATO) trial AMERICAN HEART JOURNAL
  2009; 157 (4): 599-605

- Bleeding risk with AZD6140, a reversible P2Y(12) receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
  2009; 63 (4): 667-670

- Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study LANCET
  2009; 373 (9667): 919-928

- Relation Between Aspirin Dose, All-Cause Mortality, and Bleeding in Patients With Recent Cerebrovascular or Coronary Ischemic Events (from the BRAVO Trial) AMERICAN JOURNAL OF CARDIOLOGY
  2008; 102 (10): 1285-1290

- Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes AMERICAN HEART JOURNAL
  2008; 156 (5): 826-832

- Relation Between Previous Lipid-Lowering Therapy and Infarct Size (Creatine Kinase-MB Level) in Patients Presenting With Acute Myocardial Infarction AMERICAN JOURNAL OF CARDIOLOGY
2008; 102 (9): 1119-1124

- **Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery** *JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY*
2008; 136 (5): 1149-1155

- **Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein Graft ENgineering via Transfection [PREVENT] IV)** *AMERICAN JOURNAL OF CARDIOLOGY*
2008; 102 (5): 546-551

- **Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome** *AMERICAN HEART JOURNAL*
2008; 156 (1): 177-184

- **Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation** *HEART*
2008; 94 (7): 867-873

- **Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease** *CIRCULATION*
2008; 117 (22): 2865-2874

- **Acute pharmacological conversion of atrial fibrillation to sinus rhythm - Is short-term symptomatic therapy worth it? A report from the December 2007 meeting of the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration** *CIRCULATION*
Hiatt, W. R., Lincoff, A. M., Harrington, R. A.
2008; 117 (22): 2956-2957

- **Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes** *CHEST*
2008; 133 (6): 670S-707S

- **Antithrombotic and thrombolytic therapy** *CHEST*
Hirsh, J., Guyatt, G., Albers, G. W., Harrington, R., Schunemann, H. J.
2008; 133 (6): 110S-112S

- **American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)** *CHEST*
Hirsh, J., Guyatt, G., Albers, G. W., Harrington, R., Schunemann, H. J.
2008; 133 (6): 71S-109S

- **Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).** *Chest*
Hirsh, J., Guyatt, G., Albers, G. W., Harrington, R., Schünemann, H. J., American College of Chest Physician
2008; 133 (6): 110S-112S

- **Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).** *Chest*
Hirsh, J., Guyatt, G., Albers, G. W., Harrington, R., Schünemann, H. J.
2008; 133 (6): 71S-109S

- **Acute ST-segment elevation myocardial infarction** *CHEST*
2008; 133 (6): 708S-775S

- **The primary and secondary prevention of coronary artery disease** *CHEST*
2008; 133 (6): 776S-814S
• Cockcroft-Gault versus Modification of Diet in Renal Disease - Importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with Non-ST-Segment elevation acute coronary syndromes *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
  2008; 51 (10): 991-996

• Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease *CLINICAL CARDIOLOGY*
  2008; 31 (3): 125-129

• Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites *AMERICAN JOURNAL OF CARDIOLOGY*
  2008; 101 (4): 506-509

• Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV *53rd Annual Meeting of the Southern Thoracic Surgical Association*
  ELSEVIER SCIENCE INC.2008: 494–500

• Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters *ANNALS OF THORACIC SURGERY*
  2008; 85 (2): 520-524

• Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy *CIRCULATION*
  2008; 117 (2): 192-199

• International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes *AMERICAN JOURNAL OF CARDIOLOGY*

• Time to coronary angiography and outcomes among patients with high-risk non-ST-segment-elevation acute coronary syndromes: Results from the SYNERGY trial *CIRCULATION*
  2007; 116 (23): 2669-2677

• Clinical and angiographic correlates of short- and long-term mortality in patients undergoing coronary artery bypass grafting *AMERICAN JOURNAL OF CARDIOLOGY*
  2007; 100 (10): 1538-1542

• Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidigrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
  2007; 50 (19): 1844-1851

• Inhibition of platelet aggregation by AZD6140, A reversible oral P2Y(12) receptor antagonist, compared with clopidogrel in patients with acute coronary syndrome *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
  2007; 50 (19): 1852-1856

• Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; Results from the ESPRIT trial *CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS*
Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (Results from CRUSADE) AMERICAN JOURNAL OF CARDIOLOGY
2007; 99 (10): 1389-1393

Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes EUROPEAN HEART JOURNAL
2007; 28 (10): 1193-1204

Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study EUROPEAN HEART JOURNAL
2007; 28 (9): 1109-1116

Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative) AMERICAN JOURNAL OF CARDIOLOGY
2007; 99 (9): 1222-1226

Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock - The TRIUMPH randomized controlled trial JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
2007; 297 (15): 1657-1666

Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery ANNALS OF THORACIC SURGERY
2007; 83 (3): 993-1001

Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials EUROPEAN HEART JOURNAL
2007; 28 (4): 425-432

A comparison of acute coronary syndrome care at academic and nonacademic hospitals AMERICAN JOURNAL OF MEDICINE
2007; 120 (1): 40-46

Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
2007; 69 (1): 73-83

LIPPINCOTT WILLIAMS & WILKINS.2006: 2490–97

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial AMERICAN HEART JOURNAL
2006; 152 (6): 1042-1050
- The influence of peripheral arterial disease on outcomes - A pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. *Journal of the American College of Cardiology*
  2006; 48 (8): 1567-1572

- Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes - Insights from the CRUSADE initiative. *Archives of Internal Medicine*
  2006; 166 (18): 2027-2034

- Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: Results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative. *American Heart Journal*
  2006; 152 (4): 641-647

- Clinical correlates of long-term mortality after percutaneous interventions of saphenous vein grafts. *American Heart Journal*
  Mehta, R. H., Honeycutt, E., Shaw, L. K., Glower, D., Harrington, R. A., Sketch, M. H.
  2006; 152 (4): 801-806

  2006; 355 (10): 1006-1017

- Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes. *American Journal of Cardiology*
  2006; 98 (5): 624-627

- Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft. *78th Annual Scientific Session of the American-Heart-Association*
  LIPPINCOTT WILLIAMS & WILKINS. 2006: I396–I401

- Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to reduced Clinical Events (REPLACE)-2 trial. *American Heart Journal*
  2006; 152 (1): 157-162

- The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. *American Heart Journal*
  2006; 151 (6): 1205-1213

- Statin use and sex-specific stroke outcomes in patients with vascular disease. *Stroke*
  2006; 37 (6): 1427-1431

- Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE initiative. *Journal of Thrombosis and Thrombolysis*
  2006; 21 (3): 211-220

- Association between hospital process performance and outcomes among patients with acute coronary syndromes. *JAMA-Journal of the American Medical Association*
2006; 295 (16): 1912-1920

- **Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge** *ARCHIVES OF INTERNAL MEDICINE*  
2006; 166 (7): 806-811

- **Initial experience with an intravenous P2Y(12) platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial** *AMERICAN HEART JOURNAL*  
2006; 151 (3)

- **Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes** *EUROPEAN HEART JOURNAL*  
2006; 27 (5): 527-533

- **A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*  
2006; 47 (4): 809-816

- **Cardiac tamponade in the fibrinolytic era: Analysis of >100000 patients with ST-segment elevation myocardial infarction** *AMERICAN HEART JOURNAL*  
2006; 151 (2): 316-322

- **Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*  
2006; 47 (2): 312-318

- **Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: Results from 4 large clinical trials** *AMERICAN HEART JOURNAL*  
2006; 151 (1): 16-24

- **Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery - PREVENT IV: A randomized controlled trial** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*  
2005; 294 (19): 2446-2454

- **Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery** *AMERICAN JOURNAL OF CARDIOLOGY*  
2005; 96 (9): 1254-1259

- **Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes** *AMERICAN JOURNAL OF CARDIOLOGY*  
2005; 96 (9): 1200-1206

- **The PRoject of ex-vivo vein graft ENgineering via Transfection IV (PREVENT IV) trial: Study rationale, design, and baseline patient characteristics** *AMERICAN HEART JOURNAL*  
2005; 150 (4): 643-649
- Renal function, concomitant medication use and outcomes following acute coronary syndromes. *Nephrology Dialysis Transplantation*
  2005; 20 (10): 2105-2112

- Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. *American Journal of Cardiology*
  2005; 96 (6): 750-755

- Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: Results from the prematurely terminated ADDressing the Value of facilitated ANgioplasty after Combination therapy or Epitifibatide, monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. *American Heart Journal*
  2005; 150 (1): 116-122

- Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus - An analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE-2) trial. *Journal of the American College of Cardiology*
  2005; 45 (12): 1932-1938

- Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. *American Journal of Cardiology*
  2005; 95 (12): 1404-1408

- The Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded-epitifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome - Study design and rationale. *American Heart Journal*
  2005; 149 (6): 994-1002

- Should we routinely supplement coronary patients with folate therapy to prevent in-stent restenosis? *American Heart Journal*
  Halabi, A. R., Harrington, R. A.
  2005; 149 (6): 1035-1036

- Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: Patient selection and associated treatment patterns. *Academic Emergency Medicine*
  2005; 12 (5): 431-438

- Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). *American Journal of Cardiology*
  2005; 95 (5): 611-614

- Outcomes, Health Policy, and Managed Care - Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. *American Heart Journal*
  2005; 149 (3): 474-??
• Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. *American Journal of Cardiology*
2005; 95 (3): 383-386

• Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. *European Heart Journal*

• Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a - A selective and direct factor Xa inhibitor. *Journal of Thrombosis and Thrombolysis*
2005; 18 (3): 193-197

• Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes - Results from the CRUSADE quality improvement initiative. *JAMA - Journal of the American Medical Association*
2004; 292 (17): 2096-2104

• Care of non-ST-segment elevation patients: Insights from the CRUSADE national quality improvement initiative. *1st International Quality Improvement Summit on Acute Coronary Syndromes*
MOSBY-ELSEVIER.2004: S34–S39

• Thrombolysis and adjunctive therapy in acute myocardial infarction. *Chest*
2004; 126 (3): 549S-575S

• Antithrombotic therapy during percutaneous coronary intervention - The seventh ACCP Conference on antithrombotic and thrombolytic therapy. *Chest*
2004; 126 (3): 576S-599S

• Antithrombotic therapy for coronary artery disease. *Chest*
2004; 126 (3): 513S-548S

• Highlights of the 53rd Annual Scientific Session of the American College of Cardiology - March 7-10, 2004. *Journal of the American College of Cardiology*
2004; 44 (2): 1A-1A

• Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes - A systematic overview. *JAMA - Journal of the American Medical Association*
2004; 292 (1): 89-96

• Dynamic prognostication in non-ST-elevation acute coronary syndromes: Insights from GUSTO-IIb and PURSUIT. *American Heart Journal*
2004; 148 (1): 62-71

• Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and st-segment resolution to evaluate epicardial and myocardial reperfusion. *American Journal of Cardiology*
2004; 93 (11): 1362-1367

• Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. *Canadian Journal of Cardiology*
Comparison of Bivalirudin versus heparin during percutaneous coronary intervention (the randomized evaluation of PCI linking angiomax to reduced clinical events [REPLACE]-1 trial) *AMERICAN JOURNAL OF CARDIOLOGY*
2004; 93 (9): 1092-1096

Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction *AMERICAN HEART JOURNAL*
2004; 147 (5): 847-852

Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
2004; 147 (3): 457-462

Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
2004; 43 (4): 549-556

Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes *EUROPEAN HEART JOURNAL*

Conflict of interest *AMERICAN HEART JOURNAL*
2004; 147 (2): 228-237
• Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI pilot JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2004; 2 (2): 234-241

• Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes AMERICAN JOURNAL OF MEDICINE
2004; 116 (2): 119-129

• GP IIb/IIIa blockade in elective percutaneous coronary intervention CURRENT PHARMACEUTICAL DESIGN
Dery, J. P., Harrington, R. A., Tcheng, J. E.
2004; 10 (4): 387-398

• Evaluating the benefits of glycoprotein, IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes AMERICAN HEART JOURNAL
2004; 147 (1): 84-90

• Changing the model of care for patients with acute coronary syndromes AMERICAN HEART JOURNAL
2003; 146 (4): 605-612

• Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions AMERICAN JOURNAL OF CARDIOLOGY
2003; 92 (6): 651-655

• Reduction of myocardial ischemic injury following coronary intervention (The MC-1 to eliminate necrosis and damage trial) AMERICAN JOURNAL OF CARDIOLOGY
2003; 92 (6): 660-664

• Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes AMERICAN JOURNAL OF MEDICINE
2003; 115 (4): 318-321

• Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials) AMERICAN JOURNAL OF CARDIOLOGY
2003; 92 (3): 330-333

• Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease CIRCULATION
2003; 108 (4): 399-406

• Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes AMERICAN JOURNAL OF CARDIOLOGY
2003; 92 (2): 136-140

• Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture JOURNAL OF THROMBOSIS AND THROMBOLYSIS
2003; 15 (3): 189-196


Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial. *American Heart Journal*
Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting - Results from the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial CIRCULATION
2002; 105 (3): 322-327

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials LANCET
2002; 359 (9302): 189-198

Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS) AMERICAN JOURNAL OF CARDIOLOGY
2001; 88 (5): 541-546

Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
2001; 38 (1): 1-7

Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: Results from the PURSUIT trial AMERICAN JOURNAL OF CARDIOLOGY
2001; 88 (1): 76-79

Prognostic value of ST segment depression in acute coronary syndromes: Insights from PARAGON-A applied to GUSTO-IIb JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
2001; 38 (1): 64-71

Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study LANCET
2001; 357 (9262): 1063-1068

Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes AMERICAN JOURNAL OF CARDIOLOGY
2001; 87 (5): 532-536

Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial AMERICAN HEART JOURNAL
2001; 141 (3): 391-401

Systematic adjudication of myocardial infarction end-points in an international clinical trial CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE
2001; 2 (4): 180-186

Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE
2001; 2 (4): 187-194

- Antithrombotic therapy in patients undergoing percutaneous coronary intervention. *CHEST*

- Shifting the open-artery hypothesis downstream: The quest for optimal reperfusion. *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
  2001; 37 (1): 9-18

- Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. *CIRCULATION*
  2000; 102 (24): 2952-2958

- Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition - Insights from the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial. *CIRCULATION*
  2000; 102 (10): 1093-1100

- Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: Results from PURSUIT. *36th Annual Meeting of the Society-of-Thoracic-Surgeons*
  Dyke, C. M., Bhatia, D., Lorenz, T. J., Marso, S. P., Tardiff, B. E., Hogeboom, C., Harrington, R. A.
  ELSEVIER SCIENCE INC.2000: 866–71

- Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. *71st Scientific Session of the American-Heart-Association*
  LIPPINCOTT WILLIAMS & WILKINS.2000: 728–35

- Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation results from an international trial of 9461 patients. *CIRCULATION*
  2000; 101 (22): 2557-2567

- Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. *AMERICAN HEART JOURNAL*
  2000; 139 (6): 927-933

- Age and outcome after acute coronary syndromes without persistent ST-segment elevation. *AMERICAN HEART JOURNAL*
  2000; 139 (5): 858-866

- Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes - Results from PURSUIT. *EUROPEAN HEART JOURNAL*
  2000; 21 (5): 371-381

- Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: Effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. *AMERICAN HEART JOURNAL*
  2000; 139 (3): 454-460

- Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. *CIRCULATION*
• Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial LANCET
2000; 355 (9210): 337-345

• Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
2000; 283 (3): 347-353

• Redefining medical treatment in the management of unstable angina AMERICAN JOURNAL OF MEDICINE

• Recent clinical trials in acute coronary syndromes without persistent ST elevation CURRENT OPINION IN CARDIOLOGY
Tolleson, T. R., Harrington, R. A.
1999; 14 (5): 403-411

• Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome - The platelet glycoprotein IIb IIIa in unstable angina: Receptor suppression using integrin therapy (PURSUIT) trial experience CIRCULATION
1999; 99 (22): 2892-2900

• Use of glycoprotein IIb IIIa inhibition plus fibrinolysis in acute myocardial infarction JOURNAL OF THROMBOSIS AND THROMBOLYSIS
Hudson, M. P., Greenbaum, A. B., Harrington, R. A., Ohman, E. M.
1999; 7 (3): 241-245

• Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease CIRCULATION
1998; 98 (25): 2829-2835

• Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: Pathophysiologic foundation and clinical findings Symposium on Role and Significance of Coagulation Markers in Understanding and Treating Acute Coronary Syndromes
Kleiman, N. S., Lincoff, A. M., Ohman, E. M., Harrington, R. A.
MOSBY-ELSEVIER.1998: S32–S42

• Relation between inhibition of platelet aggregation and clinical outcomes Symposium on Role and Significance of Coagulation Markers in Understanding and Treating Acute Coronary Syndromes
Harrington, R. A., Kleiman, N. S., Granger, C. B., Ohman, E. M., Berkowitz, S. D.
MOSBY-ELSEVIER.1998: S43–S50

• Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions 45th Annual Scientific Session of the American-College-of-Cardiology
ELSEVIER SCIENCE INC.1998: 936–41

• Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization 45th Annual Scientific Session of the American-College-of-Cardiology
Berkowitz, S. D., Sane, D. C., Sigmom, K. N., Shavender, J. H., Harrington, R. A., Tcheng, J. E., Topol, E. J., Califf, R. M.
ELSEVIER SCIENCE INC.1998: 311–19

• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade LANCET
1998; 352 (9122): 87-92
- **Myonecrosis after revascularization procedures** *Journal of the American College of Cardiology*


  1998; 31 (2): 241-251

- **Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention** *American Journal of Cardiology*


  1995; 76 (17): 1222-1227

- **Early clinical experience with integrerin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor** *Symposium on Prevention and Management of Thrombotic Complications during Coronary Interventions*


- **Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrerin in elective coronary intervention** *Circulation*


  1995; 91 (8): 2151-2157